| Survival to discharge (n,%) | Survival to discharge (n,%) | p-value | Adjusted OR | p-value |
---|---|---|---|---|---|
Yes, n = 182 | No, n = 266 | (95% CI) | |||
Age (years) | 0.004* | Â | Â | ||
 < 40 | 21 (11.5%) | 14 (5.3%) | |||
 40–60 | 60 (33.0%) | 62 (23.2%) | |||
 60–80 | 72 (39.6%) | 132 (49.6%) | |||
 > 80 | 29 (15.9%) | 58 (21.8%) | |||
Origin | 0.597 | Â | Â | ||
 OHCA | 152 (83.5%) | 217 (81.6%) | |||
 IHCA | 30 (16.5%) | 49 (18.4%) | |||
Gender, male | 123 (67.6%) | 163 (61.3%) | 0.173 | Â | Â |
DM | 60 (33.0%) | 123 (46.2%) | 0.005* | Â | Â |
HTN | 95 (52.2%) | 152 (57.1%) | 0.301 | Â | Â |
CAD | 45 (24.7%) | 76 (28.6%) | 0.368 | Â | Â |
HF | 23 (12.6%) | 68 (25.6%) | 0.001* | 0.51 (0.29–0.95)* | 0.021* |
COPD | 21 (11.5%) | 31 (11.7%) | 0.97 | Â | Â |
ESRD | 12 (6.6%) | 46 (17.3%) | 0.001* | 0.43 (0.21–0.89)* | 0.022* |
Malignancy | 21 (11.5%) | 38 (14.3%) | 0.398 | Â | Â |
Witness | 154 (84.6%) | 198 (74.4%) | 0.010* | Â | Â |
Bystander CPR | 132 (72.5%) | 161 (60.5%) | 0.009* | Â | Â |
Cardiac etiology | 108 (59.3%) | 109 (41.0%) |  < 0.001* |  |  |
Initial rhythm |  < 0.001* |  | 0.001* | ||
 Asystole | 46 (25.3%) | 141 (53.0%) | Reference | ||
 PEA | 51 (28.0%) | 64 (24.4%) | 2.23 (1.32–3.77)* | ||
 VT/VF | 85 (46.7%) | 60 (22.6%) | 2.69 (1.54–4.69)* | ||
CPR duration (min) | 0.105 | Â | Â | ||
 < 10 | 46 (25.3%) | 54 (20.3%) | |||
 Oct-20 | 57 (31.3%) | 70 (26.3%) | |||
 20–30 | 41 (22.5%) | 60 (22.6%) | |||
 > 30 | 38 (20.9%) | 82 (30.8%) | |||
Epinephrine dosage (mg) | 0.001* | Â | 0.038* | ||
 0–2 | 114 (62.6%) | 121 (45.5%) | Reference | ||
 2–4 | 41 (22.5%) | 68 (25.6%) | 0.86 (0.51–1.44) | ||
 4–6 | 12 (6.6%) | 27 (10.2%) | 0.70 (0.31–1.55) | ||
 > 6 | 15 (8.2%) | 50 (18.8%) | 0.36 (0.18–0.72)* | ||
ROSC SBP (mmHg) | 0.061 | Â | Â | ||
 < 100 | 32 (17.6%) | 77 (28.9%) | |||
 100–110 | 13 (7.1%) | 21 (7.9%) | |||
 110–120 | 16 (8.8%) | 23 (8.6%) | |||
 120–130 | 13 (7.1%) | 20 (7.5%) | |||
 > 130 | 108 (59.3%) | 125 (47.0%) | |||
ROSC DBP (mmHg) |  < 0.001* |  | 0.005* | ||
 < 60 | 37 (20.3%) | 103 (38.7%) | Reference | ||
 60–70 | 27 (14.8%) | 42 (15.8%) | 1.14 (0.58–2.24) | ||
 70–80 | 32 (17.6%) | 27 (10.2%) | 3.31 (1.65–6.64)* | ||
 80–90 | 26 (14.3%) | 28 (10.5%) | 2.13 (1.03–4.40)* | ||
 > 90 | 60 (33.0%) | 66 (24.8%) | 1.95 (1.11–3.42)* | ||
ROSC MBP (mmHg) | 0.003* | Â | Â | ||
 < 80 | 43 (23.6%) | 105 (39.5%) | |||
 80–90 | 19 (10.4%) | 31 (11.7%) | |||
 90–100 | 35 (19.2%) | 34 (12.8%) | |||
 100–110 | 14 (7.7%) | 24 (9.0%) | |||
 > 110 | 71 (39.0%) | 72 (27.1%) | |||
PCI | 78 (42.9%) | 45 (16.9%) |  < 0.001* | 2.62 (1.54–4.47) |  < 0.001* |